BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23640560)

  • 1. Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells.
    Zhang J; Kan Y; Tian Y; Wang Z; Zhang J
    Indian J Med Res; 2013 Mar; 137(3):527-32. PubMed ID: 23640560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells.
    Nguewa PA; Fuertes MA; Cepeda V; Alonso C; Quevedo C; Soto M; Pérez JM
    Med Chem; 2006 Jan; 2(1):47-53. PubMed ID: 16787355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.
    Wang Z; Li Y; Lv S; Tian Y
    J Int Med Res; 2013 Oct; 41(5):1577-85. PubMed ID: 24097829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
    Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
    BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
    Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
    Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells.
    Zheng YD; Xu XQ; Peng F; Yu JZ; Wu H
    Oncol Rep; 2011 May; 25(5):1399-405. PubMed ID: 21399878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits.
    Satoh M; Date I; Nakajima M; Takahashi K; Iseda K; Tamiya T; Ohmoto T; Ninomiya Y; Asari S
    Stroke; 2001 Jan; 32(1):225-31. PubMed ID: 11136941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Aminobenzamide protects primary human keratinocytes from UV-induced cell death by a poly(ADP-ribosyl)ation independent mechanism.
    Lakatos P; Szabó É; Hegedűs C; Haskó G; Gergely P; Bai P; Virág L
    Biochim Biophys Acta; 2013 Mar; 1833(3):743-51. PubMed ID: 23246565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis.
    Yoon YS; Kim JW; Kang KW; Kim YS; Choi KH; Joe CO
    J Biol Chem; 1996 Apr; 271(15):9129-34. PubMed ID: 8621564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells.
    Chen G; Zeller WJ
    Anticancer Res; 1994; 14(4A):1461-7. PubMed ID: 7979172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1.
    Chang WJ; Alvarez-Gonzalez R
    J Biol Chem; 2001 Dec; 276(50):47664-70. PubMed ID: 11577079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
    Kuang J; Wang YL; Xiao M; Tang Y; Chen WW; Song GL; Yang X; Li M
    Oncol Rep; 2014 May; 31(5):2335-43. PubMed ID: 24676941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
    Wang J; Kho DH; Zhou JY; Davis RJ; Wu GS
    Oncogene; 2017 Oct; 36(43):5939-5947. PubMed ID: 28650468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.